Drug Trial Radar · NCT04998604
EValuating trEatment RESponses of Dupilumab Versus Omalizumab in Type 2 Patients
Last checked: Nov 20, 2026Latest source record: Oct 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
360
Actual
Start
Sep 27, 2021
Primary completion
Oct 16, 2024
Study completion Dec 27, 2024
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- Collaborators
- Regeneron Pharmaceuticals
- First posted
- Aug 10, 2021
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary Objective -To evaluate the efficacy of dupilumab compared to omalizumab in reducing the polyp size and improving sense of smell Secondary Objectives * To evaluate the efficacy of dupilumab in improving chronic rhinosinusitis with nasal polyps (CRSwNP) symptoms at Week 24 compared to omalizumab * To evaluate the efficacy of dupilumab in improving CRSwNP total symptom score (TSS) at Week 24 compared to omalizumab * To evaluate the effect of dupilumab on health related quality of life (HRQoL) at week 24 compared to omalizumab * To evaluate the efficacy of dupilumab in improving nasal peak inspiratory flow at Week 24 compared to omalizumab * To evaluate the effect of dupilumab on CRSwNP overall disease severity at Week 24 compared to omalizumab * To evaluate the safety of dupilumab and omalizumab
Conditions
- Chronic Rhinosinusitis With Nasal Polyps
- Asthma
Interventions
DupilumabDrug
solution for injection subcutaneous
OmalizumabDrug
solution for injection subcutaneous
PlaceboDrug
solution for injection subcutaneous
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline to Week 24 in Nasal Polyp ScoreTime frame: Baseline (Day 1) and Week 24
- Change From Baseline to Week 24 in University of Pennsylvania Smell Identification TestTime frame: Baseline (Day 1) and Week 24
Locations
87 sites in 17 countries. Site status is shown where the registry gives one.
Cedars Sinai Medical Center Site Number : 8400026
Los Angeles, California
Asthma Allergy & Immunology Clinical Research Unit Site Number : 8400027
Tampa, Florida
Northwestern University Site Number : 8400001
Chicago, Illinois
University of Illinois
Chicago, Illinois
Advanced ENT and Allergy Site Number : 8400013
Louisville, Kentucky
University of Missouri Health Care - University Hospital Site Number : 8400016
Columbia, Missouri
Northwell Health Site Number : 8400044
Great Neck, New York
University of Rochester Site Number : 8400015
Rochester, New York
Cleveland Clinic Foundation Site Number : 8400029
Cleveland, Ohio
Optimed Research, LTD Site Number : 8400014
Columbus, Ohio
Allergy, Asthma and Clinical Research Center Site Number : 8400037
Oklahoma City, Oklahoma
Essential Medical Research, LLC Site Number : 8400024
Tulsa, Oklahoma
Oregon Health & Science University Site Number : 8400031
Portland, Oregon
University of Texas Health Science Center- Site Number : 8400019
Houston, Texas
Chryaslis Clinical Research Site Number : 8400017
St. George, Utah
Eastern Virginia Medical School Site Number : 8400010
Norfolk, Virginia
Investigational Site Number : 0560001
Ghent, Belgium
Investigational Site Number : 0560002
Leuven, Belgium
Investigational Site Number : 0560003
Woluwe-Saint-Lambert, Belgium
Investigational Site Number : 1240003
Québec, Canada
Investigational Site Number : 1240004
London, Ontario, Canada
Investigational Site Number : 1240002
Montreal, Quebec, Canada
Investigational Site Number : 2030007
Benešov, Czechia
Investigational Site Number : 2030001
Hradec Králové, Czechia
Investigational Site Number : 2030003
Ostrava - Poruba, Czechia
Investigational Site Number : 2030002
Pardubice, Czechia
Investigational Site Number : 2030012
Pilsen, Czechia
Investigational Site Number : 2030010
Prague, Czechia
Investigational Site Number : 2030006
Prague, Czechia
Investigational Site Number : 2030008
Prague, Czechia
Investigational Site Number : 2030004
Praha 5 - Motole, Czechia
Investigational Site Number : 2080003
Aarhus, Denmark
Investigational Site Number : 2080001
Copenhagen, Denmark
Investigational Site Number : 2460003
Helsinki, Finland
Investigational Site Number : 2460002
Tampere, Finland
Investigational Site Number : 2500009
Créteil, France
Investigational Site Number : 2500006
La Roche-sur-Yon, France
Investigational Site Number : 2500008
Le Kremlin-Bicêtre, France
Investigational Site Number : 2500002
Lille, France
Investigational Site Number : 2500004
Marseille, France
Showing 40 of 87 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.